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IMPORTANCE During a time with the potential for novel treatment strategies, early
detection of disease manifestations at an individual level in presymptomatic carriers of a
hexanucleotide repeat expansion in the C9orf72 gene (preSxC9) is becoming increasingly
relevant.
OBJECTIVES To evaluate changes in glucose metabolism before symptom onset of
amyotrophic lateral sclerosis or frontotemporal dementia in preSxC9 using simultaneous
fluorine 18–labeled fluorodeoxyglucose ([18F]FDG positron emission tomographic (PET) and
magnetic resonance imaging as well as the mutation’s association with clinical and fluid
biomarkers.
DESIGN, SETTING, AND PARTICIPANTS A prospective, case-control study enrolled 46
participants from November 30, 2015, until December 11, 2018. The study was conducted at
the neuromuscular reference center of the University Hospitals Leuven, Leuven, Belgium.
MAIN OUTCOMES AND MEASURES Neuroimaging data were spatially normalized and analyzed
at the voxel level at a height threshold of P < .001, cluster-level familywise error–corrected
threshold of P < .05, and statistical significance was set at P < .05 for the volume-of-interest
level analysis, using Benjamini-Hochberg correction for multiple correction. W-score maps
were computed using the individuals serving as controls as a reference to quantify the degree
of [18F]FDG PET abnormality. The threshold for abnormality on the W-score maps was
designated as an absolute W-score greater than or equal to 1.96. Neurofilament levels and
performance on cognitive and neurologic examinations were determined. All hypothesis tests
were 1-sided.
RESULTS Of the 42 included participants, there were 17 with the preSxC9 mutation
(12 women [71%]; mean [SD] age, 51 [9] years) and 25 healthy controls (12 women [48%];
mean [SD] age, 47 [10] years). Compared with control participants, significant clusters of
relative hypometabolism were found in frontotemporal regions, basal ganglia, and thalami
of preSxC9 participants and relative hypermetabolism in the peri-Rolandic region, superior
frontal gyrus, and precuneus cortex. W-score frequency maps revealed reduced glucose
metabolism with local maxima in the insular cortices, central opercular cortex, and thalami
in up to 82% of preSxC9 participants and increased glucose metabolism in the precentral
gyrus and precuneus cortex in up to 71% of preSxC9 participants. Other findings in the
preSxC9 group were upper motor neuron involvement in 10 participants (59%), cognitive
abnormalities in 5 participants (29%), and elevated neurofilament levels in 3 of 16 individuals
(19%) who underwent lumbar puncture.
CONCLUSIONS AND RELEVANCE The results suggest that [18F]FDG PET can identify glucose
metabolic changes in preSxC9 at an individual level, preceding significantly elevated
neurofilament levels and onset of symptoms.
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Amyotrophic lateral sclerosis (ALS) and frontotempo-ral dementia (FTD) are related neurodegenerative dis-orders. Amyotrophic lateral sclerosis primarily affects
the motor system with upper and lower motor neuron involve-
ment, but extramotor manifestations may occur.1-3 Fronto-
temporal dementia is the second most common form of pre-
senile dementia, caused by degeneration of frontal and anterior
temporal cortices. It affects brain regions implicated in execu-
tive control, language, behavior, and personality.4 The dis-
ease course of both ALS and FTD is progressive and invari-
ably fatal. The molecular link between ALS and FTD has been
confirmed by the discovery of the hexanucleotide repeat ex-
pansions in the 3′ untranslated region of the chromosome 9
open reading frame 72 gene (C9orf72, OMIM 614260), the most
common known monogenetic cause of both ALS and FTD.5-7
During this time of antisense oligonucleotides and other
interventional gene therapies, research in the presympto-
matic stage may contribute to the development of novel treat-
ment strategies8 and detection of individuals at risk of devel-
oping ALS and/or FTD, and ultimately lay the foundation for
future clinical studies to slow or even prevent clinical disease
manifestation.9 Presymptomatic carriers of disease-causing
mutations permit in vivo research of the brain at a unique time
to gain a better understanding of the early mechanisms that
precede the onset of symptoms.
Over the past 10 years, study findings have suggested that
several neurodegenerative diseases are preceded by an inter-
mediate presymptomatic phase.10,11 Research in presympto-
matic carriers of a hexanucleotide repeat expansion in the
C9orf72 gene (preSxC9) reported the occurrence of cognitive
and behavioral changes, neuropsychiatric symptoms, and de-
generation of gray matter (GM) and white matter (WM).12-21
Neurofilaments (Nfs), such as neurofilament light chain
(NfL) and phosphorylated neurofilament heavy chain (pNfH),
have been studied extensively in ALS and FTD. Elevated lev-
els of NfL and pNfH, both markers of neuronal injury and neu-
rodegeneration, demonstrated high diagnostic performance.22
Previous research has shown that NfL is increased in sympto-
matic, but not presymptomatic, preSxC9 at the group level.23
Recent studies suggested that a slow increase in Nf levels can
be observed in presymptomatic individuals who carry the mu-
tation as far as 3.5 years before diagnosable illness,24-26 while
another study described an association between higher NfL lev-
els and GM atrophy.27
It has often been suggested that assessing glucose me-
tabolism using positron emission tomographic (PET) imaging
with fluorine 18–labeled fluorodeoxyglucose ([18F]FDG) is a use-
ful diagnostic marker in the earliest stage of ALS and FTD.28-31
Moreover, [18F]FDG PET imaging serves as a relevant bio-
marker for disease staging, cognitive impairment, and sur-
vival prediction.29,32
However, little is known about the glucose metabolic
changes that may occur before clinical disease manifestation
in preSxC9. The goal of our study was to evaluate changes in
glucose metabolism that occur before diagnosable illness, ie,
the presymptomatic disease stage,33 in preSxC9. In addition,
we wanted to explore the association between cerebral glu-
cose metabolism and other known indicators of disease, such
as Nf levels in cerebrospinal fluid (CSF), neuropsychological
capacities, and clinical neurologic examination.
Methods
Participants
A total of 29 healthy individuals serving as controls were in-
cluded in this study, of whom 25 were considered in the analy-
sis. None of the volunteers had a first-degree relative with
dementia or a history of neurologic illness, psychiatric ill-
ness, or substance use. Participants with brain lesions noted
on structural magnetic resonance imaging (MRI) were ex-
cluded. Demographic characteristics are detailed in Table 1.
The study was conducted from November 30, 2015, to
December 11, 2018, at the neuromuscular reference center of
the University Hospitals Leuven, Leuven, Belgium. All partici-
pants provided written informed consent, and this study was
approved by the ethics committee of the University Hospitals
Leuven, Leuven, Belgium. This study followed the Strength-
ening the Reporting of Observational Studies in Epidemiol-
ogy (STROBE) reporting guideline for case-control studies.
We compared the Nf levels in the preSxC9 group with those
of a control group (n = 10; mean [SD] age, 49 [14] years) pre-
viously reported.34 A consecutive series of 17 preSxC9 partici-
pants was included in this study. A pathogenic expansion of
C9orf72 was considered as having more than 30 repeats. All
preSxC9 participants were native Flemish speakers, and their
educational levels were between 3 ([upper] secondary educa-
tion) and 6 (second stage of tertiary education) on the Inter-
national Standard Classification of Education scale.35 None of
the preSxC9 participants met the clinical diagnostic criteria
for ALS or FTD.36,37 Exclusion criteria were the presence of clini-
cally apparent ALS or FTD, severe and chronic illness, sub-
stance use, and traumatic brain injury.
Key Points
Question Can metabolic brain changes be detected in
presymptomatic individuals who are carriers of a hexanucleotide
repeat expansion in the C9orf72 gene (preSxC9) using
time-of-flight fluorine 18–labeled fluorodeoxyglucose positron
emission tomographic imaging and magnetic resonance imaging,
and what is the association between the mutation and clinical and
fluid biomarkers of amyotrophic lateral sclerosis and
frontotemporal dementia?
Findings In a case-control study including 17 preSxC9 participants
and 25 healthy controls, fluorine 18–labeled fluorodeoxyglucose
positron emission tomographic imaging noted significant clusters
of relative hypometabolism in frontotemporal regions, the insular
cortices, basal ganglia, and thalami in the preSxC9 participants.
Use of this strategy allowed detection of changes at an individual
level.
Meaning Glucose metabolic changes appear to occur early in
the sequence of events leading to manifest amyotrophic lateral
sclerosis and frontotemporal dementia. Fluorine 18–labeled
fluorodeoxyglucose positron emission tomographic imaging may
provide a sensitive biomarker of a presymptomatic phase of
disease.
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All participants with preSxC9 were evaluated with the
Dutch version of the Edinburgh Cognitive and Behavioral ALS
Screen (ECAS) by an experienced neuropsychologist (J.D.V.).35
The ECAS is a brief, multidomain screening battery that as-
sesses cognitive functions typically affected in patients with
ALS (language, verbal fluency, and executive functioning), as
well as cognitive functions not typically affected in patients
with ALS (memory, visuospatial functioning).38 Dutch norma-
tive data were used, with the fifth percentile as a threshold for
abnormality.35 Results of the ECAS are presented in Table 2.
All of preSxC9 participants underwent a standard clinical
neurologic examination by a neurologist experienced in neu-
romuscular disorders (P.V.D.).
Sixteen of 17 preSxC9 participants agreed to undergo a lum-
bar puncture according to standardized protocol at the Uni-
versity Hospitals Leuven to determine the Nf levels in the CSF
within 48 hours following the [18F]FDG PET MRI scan. Neu-
rofilament levels in CSF were measured using commercially
available kits for NfL (UD51001, with an intraassay variability
of 1.6% and interassay variability of 8.7%; UmanDiagnostics
AB) and pNfH (with an intraassay variability of 5.2% and in-
terassay variability of 8.7%; Euroimmun AG). Assessment of
Nf levels was done using predefined diagnostic cutoff values
for NfL (1227 pg/mL)34 and pNfH (750 pg/mL).39
All participants underwent simultaneous [18F]FDG PET and
MR imaging on a hybrid scanner (Signa PET/MR, release MP26;
GE Healthcare) with integrated time-of-flight PET scan acqui-
sition and 3-T MRI. All participants fasted for at least 6 hours
before [18F]FDG administration. [18F]FDG was injected intra-
venously as a bolus (mean [SD], controls: 153 [11] MBq; preSxC9:
149 [6] MBq).
The [18F]FDG PET images were acquired in list mode for
25 minutes (30 minutes postinjection). The PET images were
reconstructed with ordered subset maximum likelihood ex-
pectation maximization with 4 iterations and 28 subsets fol-
lowed by postfiltering with 4.5-mm gaussian postsmoothing
in the transaxial direction and standard smoothing along the
Z direction. Images had an initial voxel size of 1.56 × 1.56 × 2.78
mm3. A vendor-provided, atlas-based method was used for at-
tenuation correction.40
Simultaneous to the PET acquisition, a 3-dimensional volu-
metric sagittal T1-weighted image (3D BRAVO, repetition time/
echo time [TR/TE] = 8.5/3.2 milliseconds, 0.6 × 1 × 1 mm3 voxel
size, dimensions: 312 × 256 × 256 voxels) and T2-weighted
fluid-attenuated inversion recovery image (3D CUBE, TR/
TE = 8500/130 milliseconds, 0.7 × 1 × 1 mm3 voxel size, di-
mensions: 268 × 256 × 256 voxels) were acquired.
Statistical Analysis
Statistical analyses of clinical data were performed using
SPSS software, version 25 (IBM Software) and GraphPad
Prism, version 8.0 (GraphPad Software). Demographic char-
acteristics and clinical test results were compared between
groups using a χ2 test for dichotomous and categorical
variables or Mann-Whitney test for numeric variables. All
hypothesis tests were 1-sided, and statistical significance
was set at P < .05.







group difference P value
Age, mean (SD), y 51 (9) 47 (10) Mann-Whitney, 154 .13
Sex, No. (%)
Women 12 (71) 12 (48) χ 21 = 2.11
.13
Men 5 (29) 13 (52)
Educational level, ISCED, No. (%)a
0-4 7 (41) 8 (32) χ 21 = 0.37 .39
5-6 10 (59) 17 (68) NA NA
MMSE score, median (range)b 29 (26-30) 30 (28-30) Mann-Whitney, 156.5 .12
BDI, median (range)c NA 2 (0-5) NA NA
Psychiatric drugs, No. (%) 1 (6) NA NA NA
Antidepressants, No. (%) 1 (6) NA NA NA
Abbreviations: BDI, Beck Depression
Inventory; ISCED, International
Standard Classification of Education
Scale; MMSE, Mini-Mental-State
Examination; NA, not applicable;
preSxC9, presymptomatic carrier of
a hexanucleotide repeat expansion in
the C9orf72 gene.
a Categorized according to the ISCED
1997 definitions. Scale numbers
represent nontertiary education,
0-4, and tertiary education, 5-6.
b Total score ranges, 0 to 30; lower
scores indicate worse cognitive
function.
c Total score ranges, 0 to 63; higher
scores indicate more severe
depressive symptoms.
Table 2. Clinical Characteristics in PreSxC9 Participants
Characteristic Median (range)
Percentile rank
scores ≤5%, No. (%)
ECAS performancea
Total score 117 (93-124) 1 (6)
ALS specificb
Total score 86 (69-92) 1 (6)
Language 28 (25-28) 0
Verbal fluency 20 (14-20) 1 (6)
Executive functions 39 (26-44) 3 (18)
ALS nonspecificc
Total score (of 36) 30 (23-33) 0




Abbreviations: ALS, amyotrophic lateral sclerosis; ECAS, Edinburgh Cognitive
and Behavioral ALS Screen; preSxC9, presymptomatic carrier of a
hexanucleotide repeat expansion in the C9orf72 gene.
a Possible score range, 0 to 136; lower scores indicate more severe cognitive
dysfunction.
b Evaluates functions typically affected in ALS. Total score ranges from 0 to 100;
language, 0 to 28; verbal fluency, 0 to 20; and executive functions, 0 to 42.
Lower scores indicate more severe cognitive dysfunction.
c Evaluates cognitive functions not typically affected in ALS. Total score ranges
from 0 to 36; memory, 0 to 24; and visuospatial functions, 0 to 12. Lower
scores indicate more severe cognitive dysfunction.
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Image Analysis
ANTS, version 2.1.0., and SPM, version 12 (Wellcome Trust Cen-
tre for Neuroimaging) software, combined with in-house scripts
implemented in Matlab (R2018b; The MathWorks Inc), were
used to process the T1-weighted and fluid-attenuated inver-
sion recovery images. After visual inspection of the raw T1 im-
ages, the T1 images were processed in native space using the
antsCorticalThickness pipeline in ANTS,39 which performs a
brain extraction and segments the image of the individual’s
brain by means of 5 specific tissue priors: CSF, cortical GM, WM,
subcortical GM, and the brainstem. After visual inspection
of the segmentations, 3 control scans were excluded because
of poor image quality and subsequent suboptimal brain data
extraction and segmentation. Gray matter tissue probability
maps were warped to the Nathan Kline Institute template
(Rockland Sample, dimensions = 182 × 218 × 182 voxels), which
was warped to Montreal Neurological Institute space (voxel
size = 1 × 1 × 1 mm3, matrix = 182 × 218 × 182) and modu-
lated with the jacobian warp parameters, all using nonlinear
symmetric diffeomorphic registration.
All [18F]FDG PET images were first quality checked for com-
plete acquisition and motion, then dynamically recon-
structed and corrected for potential head motion. The frames,
which were reconstructed over a series of 5 minutes, were then
averaged. After visual inspection, PET images were coregis-
tered to their respective native MRI and spatially normalized
to Montreal Neurological Institute space using ANTS, apply-
ing the normalization parameters described above. After vi-
sual inspection, 1 control scan was considered an outlier (>3
SD from the mean) and subsequently excluded. The [18F]FDG
PET images were corrected for partial volume effects with the
Müller-Gartner method (PMOD, version 3.9), which consid-
ers both GM spill-out and WM spill-in based on the MRI-
based GM and WM tissue probability maps. Partial volume cor-
rection (PVC) was done using a point-spread function with a
5.5-mm isotropic full width at half maximum to mimic the PET
image resolution, while a regression approach was applied for
all voxels with a WM probability greater than 0.95 to deter-
mine the [18F]FDG uptake in WM. The GM probability thresh-
old was set at 0.3 to correct uptake values of GM voxels for
WM activity. Partial volume effect–corrected [18F]FDG PET
images were spatially normalized to Montreal Neurological
Institute space using ANTS, applying the normalization param-
eters described above.
For the group comparison, both MR and [18F]FDG PET im-
ages were smoothed with an isotropic gaussian smoothing ker-
nel of 8-mm full width at half maximum to blur individual
variations. Owing to a difference in ambient conditions (ie, vi-
sual input) following tracer injection, the occipital lobe was ex-
cluded from all neuroimaging analyses. All PET images were
proportionally normalized to the average activity in a GM mask
generated from the voxel-based morphometry comparative
analysis applying an absolute threshold of 0.1 (excluding the
occipital lobe).
The spatially normalized and smoothed images were then
entered into a generalized linear model. All hypothesis tests
were 1-sided, with a height threshold of P < .001 and a cluster-
level familywise error (FWE)-corrected threshold of P < .05,
applying a minimum extent threshold of 150 voxels for the
[18F]FDG PET analyses. Age was included as a nuisance covar-
iate in [18F]FDG PET analyses as well as in the voxel-based mor-
phometry analyses, where total intracranial volume was also
considered a nuisance variable. The Talairach atlas41 was used
to define Brodmann areas and the Harvard-Oxford Atlas42-45
was used for the anatomic localization of significant clusters.
A volume-of-interest–based analysis after region-based
voxelwise correction for GM atrophy was conducted using the
Hammers N30R83 maximum probability atlas to confirm our
findings at the voxel level in PMOD, version 3.9 (PMOD Inc) and
SPSS, version 25 (IBM Software). We applied the Benjamini-
Hochberg method to correct for multiple testing.
W-Score Maps
W-score maps ([raw value for each patient − value expected
in the control group for the patient’s age] / SD of the residuals
in the control group) were computed for preSxC9 using the con-
trol group as a reference to quantify the degree of [18F]FDG PET
imaging abnormality at the voxel level. W-score maps are analo-
gous to z-score maps, adjusted for covariates of interest. For
our study, we considered age as a covariate of interest.46 The
threshold for abnormality was defined as an absolute
W-score greater than or equal to 1.96, which corresponds to
95% of the area under the curve in a normal distribution. Hy-
pometabolic maps, binarized at a W-score less than or equal
to −1.96, and hypermetabolic maps, binarized at a W-score
greater than or equal to 1.96, were summed across partici-
pants to generate W-score frequency maps to illustrate the frac-
tion of preSxC9 participants surpassing the threshold for ab-
normality at the voxel level.
Results
A total of 46 participants (17 preSxC9 and 29 healthy con-
trols) were included in this study. After data inspection, all
preSxC9 participants (mean [SD] age, 51 [9] years; 12 women
[71%], 5 men [29%]) and 25 (4 of 29 excluded owing to poor
image quality) healthy controls (mean [SD] age, 47 [10] years;
12 women [48%], 13 men [25%]) were considered for the analy-
ses. The demographics of the study population are given in
Table 1. The preSxC9 and control groups did not differ signifi-
cantly in sex distribution (χ21 = 2.11; P = .13), educational level
(χ21 = 0.37; P = .39), or age (Mann-Whitney, 1.54; P = .13).
Neuroimaging
Relative glucose metabolism was compared between the
preSxC9 and control cohorts. This analysis revealed signifi-
cant clusters of relative hypometabolism in the preSxC9 group
compared with the control group (range, 27%-36%) situated
in the basal ganglia, thalamus, and frontotemporal and insu-
lar cortices. All analyses were thresholded at a height of P < .001
and FWE-corrected level of P < .05 at the cluster level (Figure 1;
eTable 1 in the Supplement). At the group level, we observed
no significant clusters of relative hypermetabolism.
The comparative voxel-based volumetric analysis (voxel-
based morphometry) revealed significant clusters of reduced
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GM volume (range, 19%-25%) located in the frontotemporal
regions, including the peri-Rolandic region, insular cortices,
basal ganglia, and thalami. All analyses were thresholded at a
height of P < .001 and FWE-corrected level of P < .05 at the
cluster level (Figure 1; eTable 2 in the Supplement). A voxel-
based regression analysis of the association between age and
GM volume failed to show a significant difference in the slopes
of the preSxC9 and control participants.
The [18F]FDG PET imaging data were also analyzed with
partial volume effect correction to account for GM atrophy. Sig-
nificant clusters of relative hypometabolism (range, 16%-
22%) persisted in frontotemporal regions, including the insu-
lar cortices, as well as the basal ganglia and thalami. All analyses
were thresholded at a height of P < .001 and FWE-corrected
level of P < .05 at the cluster level (Figure 1; eTable 3 in the
Supplement; Video). A voxel-based regression analysis of
the association between age and cerebral metabolism failed
to show a significant difference in the slopes of the preSxC9
and healthy control participants.
These findings were supported in a volume-of-interest–
based analysis applying region-based voxelwise correction for
GM atrophy (eFigure 1 and eTable 5 in the Supplement). Sig-
nificant clusters of relative hypermetabolism (range, 6%-7%)
emerged in the peri-Rolandic region, the superior frontal gy-
rus, and the precuneus cortex following PVC. All analyses were
thresholded at a height of P < .001 and FWE-corrected level
of P < .05 at the cluster level (Figure 1; eTable 4 in the Supple-
ment; Video). To confirm the presence of relative hypermeta-
bolic clusters in preSxC9 participants, the analysis was re-
peated using standardized uptake value ratio images; cortical
uptake was scaled to the average uptake in cerebellar struc-
tures not reported as being affected by a mutation in the
C9orf72 gene, supporting our findings (eResults, eFigure 4,
eTable 6 in the Supplement).47
Figure 1. Relative Glucose Metabolism and Gray Matter Volume in Presymptomatic Carriers of a Hexanucleotide Repeat Expansion
in the C9orf72 Gene (PreSxC9) Corrected for Age on Axial, Coronal, and Sagittal Sections
[18F]FDG PET relative hypometabolismA
Voxel-based morphometryB
[18F]FDG PET PVC relative hypometabolismC
[18F]FDG PET PVC relative hypermetabolismD
z = –14 z = –4 z = 10 y = –14 y = –1 y = 9 x = –6 x = 6 x = 50
z = 30 z = 54 z = 66 y = –8 y = –14 y = –66 x = –24 x = –6 x = 12
2 5t 2 5t
Reduced glucose metabolism and gray matter volume depicted in red-yellow,
and increased glucose metabolism depicted in blue-white. Data were analyzed
at a height threshold of P < .001 and were cluster level corrected for familywise
error at P < .05. A, Projections of areas with relative hypometabolism in
preSxC9 participants vs healthy controls. B, Volume decline in preSxC9
participants vs healthy controls. C, Relative hypometabolism in preSxC9
participants and healthy controls following voxel-based PVC. D, Relative
hypermetabolism in preSxC9 and healthy controls following voxel-based PVC.
[18F]FDG indicates fluorine 18–labeled fluorodeoxyglucose; PET, positron
emission tomography; PVC, partial volume correction; and t, t value. Section
numbers refer to Montreal Neurological Institute coordinates.
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Clinical Parameters
Neurologic examination revealed mild signs of upper motor
neuron (UMN) abnormalities in 12 of the 17 preSxC9 partici-
pants (71%). As the presence of a Hoffman sign or ankle clo-
nus is not necessarily abnormal in young people, we only
considered the presence of a jaw jerk, a Babinski sign, hyper-
reflexia, and increased muscle tone for further analyses. This
was apparent overall in 10 preSxC9 participants (59%). In 5 par-
ticipants (29%) increased muscle tone was observed in the
lower extremities; 1 (6%) also presented with increased muscle
tone in upper extremities.
Five participants (29%) of the preSxC9 cohort presented
with abnormal neuropsychological performance. Executive
functioning was affected in 3 preSxC9 participants (18%), 1 par-
ticipant presented with isolated abnormal performance on ver-
bal fluency, and another individual showed isolated impair-
ment on the memory subdomain (Table 2).
Examination of the CSF showed median NfL levels of 652
pg/mL (range, 276-1510) and pNfH levels of 195 pg/mL (range,
123-490). The NfL and pNfH levels did not differ significantly
between the preSxC9 and healthy controls at the group level.
However, elevated NfL levels, ie, surpassing the diagnostic cut-
off, were observed at the individual level in the CSF of 19% of
the preSxC9 group (Figure 2). All 3 of the 16 who underwent
lumbar puncture displayed signs of UMN involvement on clini-
cal neurologic examination, and 1 of the 3 individuals with el-
evated Nf levels displayed an abnormal score on the memory
domain using the ECAS. The pNfH levels in the CSF remained
within the reference range in all preSxC9 participants (Figure 2).
We were unable to identify a significant association be-
tween relative tracer uptake and age, UMN involvement, ECAS
performance, or Nf levels in CSF at the group level in preSxC9
participants using regression analyses at a height-corrected
threshold of P < .001 and with a cluster-level FWE-corrected
threshold of P < .05. Similarly, no significant association was
identified between GM volume and age, UMN involvement,
ECAS performance, or Nf levels in CSF, applying the same
threshold for significance.
We generated voxel-level W-score maps to evaluate how
many preSxC9 participants presented with suprathreshold
voxels in key regions. A frequency image of the W-score maps,
generated from the [18F]FDG PET images without correcting
for partial volume effect, showed that 14 preSxC9 partici-
pants (82%) had significantly reduced tracer uptake in the in-
sular cortices, central opercular cortex, and thalami (eFig-
ure 2A in the Supplement). In addition, a frequency image of
the W-score maps, generated from the [18F]FDG PET images
corrected for partial volume effect, showed that up to 71% of
preSxC9 patients had significantly increased tracer uptake,
surpassing the predefined threshold of an absolute W-score of
1.96, which corresponds to the 2.5th percentile on both sides
in the peri-Rolandic region (eFigure 2B in the Supplement). A
mean image of the W-score maps in the preSxC9 cohort re-
flected the consistency of the changes observed at the group
level (eFigure 3 in the Supplement). Individual W-score maps
of relative hypometabolism supported the pattern observed
at the group level in up to 82% of preSxC9 participants
(Figure 3). A W-score frequency map of GM volume reduction
revealed suprathreshold voxels in the thalami and central oper-
cular cortex in 11 preSxC9 participants (65%) (eFigure 2C in the
Supplement). In addition, using the W-score maps, we were
unable to identify a clear association between the extent of ab-
normality and UMN involvement, ECAS performance, and Nf
levels in CSF.
Discussion
A voxelwise comparison of glucose metabolic patterns re-
vealed clusters of relative glucose hypometabolism situated
in frontotemporal and insular cortices, the basal ganglia, and
thalami. Moreover, GM volume reductions revealed a wide-
spread neuroanatomic signature in the frontotemporal and in-
sular cortices, basal ganglia, and thalami. The observed volu-
metric differences are consistent with structural changes
reported in previous studies of preSxC9.13 Even though re-
gional hypometabolism in subcortical and extramotor re-
gions may be explained in part by neuronal loss, the func-
tional disruption identified by [18F]FDG PET imaging was
supported, as clusters of reduced glucose metabolism in afore-
mentioned regions withstood PVC, and thus correction for
GM atrophy.
Significant clusters of relative hypermetabolism were ob-
served in the precentral and superior frontal gyrus and the pre-
cuneus cortex following PVC. This finding may be inter-
preted as compensatory neuronal activity or a possible
abnormal function of cortico-striatal-thalamic-cortical cir-
cuits resulting in UMN abnormalities. In addition, we can
Figure 2. Neurofilament Levels in the Cerebrospinal Fluid (CSF) of Presymptomatic Carriers





















































CSF levels of phosphorylated heavy chainB
A, Neurofilament light chain in the
CSF of healthy controls and preSxC9
participants. B, Phosphorylated
neurofilament heavy chain in the CSF
of healthy controls and preSxC9
participants. The dotted line indicates
diagnostic cutoff level. The upward
arrowheads indicate the controls, and
the downward arrowheads indicate
the preSxC9 participants. Error bars
indicate 95% CIs.
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speculate that the observed clusters of relative hypermetabo-
lism reflect neuroinflammation associated with activated
astrocytes or microglia.29
The observed structural and metabolic changes in the
preSxC9 participants suggest that brain regions correspond-
ing to cognitive and motor processes are impaired in the pre-
symptomatic stage of ALS and FTD. These findings are in line
with previous [18F]FDG PET imaging studies in symptomatic
carriers of a C9orf72 hexanucleotide repeat expansion, dem-
onstrating relative hypometabolism in frontotemporal and sub-
cortical regions.48,49 Moreover, our findings support the role
of the thalamus in C9-related disease.49,50
The role of the cerebellum in C9-related disease remains
unclear. A recent voxel-based morphometry study from the
multicenter Genetic Frontotemporal Dementia Initiative con-
sortium described GM volume reductions in the superior-
posterior cerebellum.14 We, however, did not observe signifi-
cant GM volume reductions in the cerebellum, supporting the
findings of another study.15 To our knowledge, there are no con-
sistent findings on volumetric changes in the cerebellum of
preSxC9 individuals.
For this study, W-score maps were generated to observe in-
dividual effects, as individual differences may have been washed
out in a group-level voxel-based analysis. W-score frequency
maps reflected the consistency of the pattern observed at the
group level in individual W-score maps of a number of preSxC9
participants. These maps demonstrated that the highest fre-
quencies (up to 82%) of reduced glucose metabolic uptake,
below the threshold for abnormality, were found in the insular
cortices, central opercular cortex, and thalami of preSxC9
participants. The highest frequencies (up to 71%) of increased
glucose metabolism, above the threshold for abnormality, fol-
Figure 3. Individual W-Score Maps of Relative Hypometabolism Observed in PreSxC9 Participants
z = 10 y = –14 x = –6 z = 10 y = –14 x = –6 z = 10 y = –14 x = –6
–1.96 –4w
Age, 30-40 y Age, 40-55 y Age, 55-60 y
Thresholds for W-score maps were set at a W score less than or equal to −1.96
and sorted by age, displayed on axial (z = 10), coronal (y = −14), and sagittal
(x = −6) sections. Section numbers refer to Montreal Neurological Institute
coordinates. Images from participants with elevated neurofilament levels are
within red boxes. w indicates W score.
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lowing PVC were found in the peri-Rolandic region and supe-
rior frontal gyrus of the preSxC9 participants. Given that only
part of the preSxC9 cohort had cognitive, pyramidal, or Nf
changes, we suggest that the metabolic changes may occur early
in the sequence of events leading to manifest ALS and FTD.
Because the age at disease onset is variable in C9orf72 re-
peat expansion carriers, the preSxC9 cohort in the present
study most likely consists of a mixture of individuals who are
relatively close to or far from disease onset. In addition, a hexa-
nucleotide repeat expansion is known to be associated with a
clinically heterogeneous disease spectrum.2 The conceivable
high degree of clinical variability within the preSxC9 group
could potentially blur correlations with clinical parameters. As
we did not observe an association with deviation from the norm
and increasing age, longitudinal studies are needed to estab-
lish how the patterns of hypometabolism evolve and their pre-
dictive value for clinical disease onset.
We did not identify significant differences in CSF Nf lev-
els at the group level between healthy controls and preSxC9
participants. Other studies were also unable to identify sig-
nificant differences for this marker for axonal injury between
healthy controls and individuals who are preSxC9.24,51 At the
individual level, NfL appears to be more sensitive than pNfH
in the phase preceding diagnosable illness: no preSxC9 par-
ticipant displayed a pathologic increase in pNfH, but 3 preSxC9
participants displayed abnormally high NfL levels.
We did not identify a significant association between Nf
levels,ECASperformance,clinicalneurologicscreening,andfind-
ings on neuroimaging. This finding may, at least in part, be ex-
plained by sample size, as few preSxC9 participants presented
with cognitive changes, elevated Nf levels, and UMN signs.
Changes in cerebral metabolism may also precede clinical signs,
which is in line with a recent study describing functional reorga-
nizationandnetworkresilienceinindividualswhoarepreSxC9.18
Longitudinal, multimodal PET and MRI studies are needed
to gain a better understanding of the sequence of events that
precede diagnosable illness. In addition, no significant associa-
tion was observed between GM volume and increasing age in
the preSxC9 cohort. We could therefore speculate that the ob-
served volumetric differences between the preSxC9 and healthy
control participants may represent not only GM atrophy but may,
at least in part, indicate neurodevelopmental differences. Ado-
lescent neuroimaging studies could assist in gaining more in-
sight into the natural history of brain development in preSxC9.
Limitations
This study has limitations. First, the sample size was rela-
tively small, which may have been a factor in the power of
group comparisons for signs of upper motor neuron involve-
ment and the association between neuroimaging data and clini-
cal indicators of disease. Second, the absence of convertors in
our cohort prevented us from exploring the predictive values
of these markers for diagnosis. Third, we did not perform neu-
rologic examinations in the control cohort. We also did not use
cognitive screening with the ECAS in the healthy controls; how-
ever, we administered a Mini-Mental-State Examination in all
participants, which did not reflect any cognitive abnormali-
ties. Fourth, the difference in ambient conditions (visual in-
put) between the preSxC9 and control cohorts necessitated
masking the occipital lobe from our comparative analyses be-
tween preSxC9 and healthy controls, therefore preventing us
from performing a whole-brain, voxel-based comparative
analysis. However, to ensure the robustness of the patterns of
relative hypometabolism, we performed a second whole-
brain analysis in the preSxC9 group. This second analysis re-
vealed the same clusters that we observed previously as well
as a cluster of relative hypermetabolism in the occipital lobe,
supporting our findings.
Conclusions
This study showed regional glucose metabolic alterations in
presymptomatic carriers of a C9orf72 hexanucleotide repeat
expansion before diagnosable illness that remained after cor-
rection for volume differences. Within the preSxC9 cohort on
W-score maps of [18F]FDG PET images, up to 82% (n = 14) pre-
sented with voxels surpassing the threshold of abnormality in
key regions, Nf levels were elevated in only 19% (n = 3), de-
viation from the norm according to ECAS performance was
observed in 29% (n = 5), 59% (n = 10) presented with subtle
UMN signs, and abnormalities were noted on W-score maps
on MR images in 65% (n = 11). The individual W-score image
suggests that [18F]FDG PET might be able to detect neuronal
injury in an earlier stage than motor or cognitive changes or
Nf levels.
To our knowledge, this is the first study that closely ex-
amines cerebral glucose metabolism in preSxC9 carriers and
its association with GM volume and indicators of disease. Our
findings suggest that [18F]FDG PET imaging could provide a
sensitive biomarker of a presymptomatic phase of disease,
which can be of relevance for future therapeutic strategies.
Multimodal and longitudinal imaging studies with an aug-
mented sample size are needed to gain more insight into the
sequence of events in the presymptomatic stage of C9orf72-
related disease.
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